Company: SION
Filing Date: 2025-02-03
Form Type: S-1/A
Source: 0001193125-25-018825
Chunk: 120

Company: Sionna Therapeutics, Inc.
Filing Date: 2025-02-03
Form: S-1/A
Chunk 120
---
 contained in this prospectus, including statements regarding our future results of operations and financial position, business strategy, product candidates, preclinical studies and clinical trials, results of preclinical studies and clinical trials, research and development costs, regulatory approvals, commercial strategy, timing and likelihood of success, as well as plans and objectives of management for future operations, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that are in some cases beyond our control and may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “would,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. Forward-looking statements contained in this prospectus include, but are not limited to, statements about:

| • |     | the initiation, timing, progress and results of our research and development programs, preclinical studies and clinical 
 trials;                                                                                                                 |

| • |     | the ability of clinical trials to demonstrate safety and efficacy of our product candidates, and other positive results, 
 and the ability of our preclinical studies to predict later clinical trial results;                                      |

| • |     | the timing, scope and likelihood of regulatory filings and approvals of our product candidates; |

| • |     | the implementation of our business model, and strategic plans for our business, programs, and current and future product 
 candidates;                                                                                                              |

| • |     | our ability to obtain additional cash and the sufficiency of our existing cash, cash equivalents and investments in 
 marketable securities to fund our future operating expenses and capital expenditure requirements;                   |

| • |     | the accuracy of our estimates regarding expenses, preliminary financial information, future revenue, capital requirements 
 and needs for additional financing;                                                                                       |

| • |     | the size and growth potential of the markets for our product candidates, and our ability to serve those markets; our                                                                                                                                    
 potential and ability to successfully manufacture and supply our current and future product candidates for clinical trials and for commercial use, if approved; the scope of protection we are able to establish and maintain for intellectual property 
 rights covering our product candidates;                                                                                                                                                                                                                 |

| • |     | developments relating to our